Breeze Airways announced Tuesday it will begin offering new nonstop service from Manchester-Boston Regional Airport (MHT) to ...

Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its ...

Novo Nordisk NOVO.B 1.19% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date.

Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's ...

(RTTNews) - Novo Nordisk (NVO) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to update the Ozempic (once ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...